HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

Pyxis Oncology, Inc. +9.52% Pre

Pyxis Oncology, Inc.

PYXS

1.61

1.61

+9.52%

0.00% Pre
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ: PYXS) with a Buy and maintains $7 price target.